Skip to main content
. 2021 Nov 3;35(6):3345–3353. doi: 10.21873/invivo.12632

Table III. Levels of MPs and procoagulant activity in relation to cytoreductive treatment in MPN patients.

graphic file with name in_vivo-35-3349-i0001.jpg

1Values denote median and interquartile range. PMPs: Platelet microparticles; RMPs: erythrocyte microparticles; MP-activity: procoagulant activity of microparticles; n-s: number of samples. *p<0.05.